ទំព័រដើម › មហារីកទ្រូង › វ៉ាស៊ីនតោន › Seattle
ការសាកល្បងគ្លីនិកសម្រាប់ មហារីកទ្រូង នៅក្នុង Seattle, WA
ការសិក្សាចំនួន 39 សម្រាប់ មហារីកទ្រូង កំពុងរកអ្នកចូលរួមនៅតាមទីតាំងក្នុង និងជុំវិញ Seattle (ក្នុងចម្ងាយប្រហែល 30 ម៉ាយ)។ បើកការសិក្សាមួយដើម្បីមើលថាតើនរណាអាចចូលរួម និងរបៀបទំនាក់ទំនងទៅកាន់ក្រុមការងារសិក្សា។
អត្ថបទសិក្សាផ្លូវការ (អង់គ្លេស)
កំពុងរកអ្នកចូលរួមសម្រាប់ការសិក្សាមួយនៅទីនេះ? លេចធ្លោនៅផ្នែកខាងលើនៃទំព័រនេះ — $99 សម្រាប់ 30 ថ្ងៃ →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- University of Washington, Fred Hutchinson Cancer Center, Seattle
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
កំពុងជ្រើសរើសការសិក្សាសង្កេតស្វាគមន៍អ្នកស្ម័គ្រចិត្តដែលមានសុខភាពល្អ
- Swedish Medical Center-Ballard Campus, Seattle
- Swedish Medical Center-Cherry Hill, Seattle
- Swedish Medical Center-First Hill, Seattle
- និង 1 ទៀត
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Fred Hutchinson Cancer Center, Seattle
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Fred Hutchinson Cancer Research Center, Seattle
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Fred Hutchinson Cancer Research Center, Seattle
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
កំពុងជ្រើសរើសដំណាក់កាល 3
- Fred Hutchinson Cancer Center ( Site 0069), Seattle
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
កំពុងជ្រើសរើសដំណាក់កាល 2
- Fred Hutchinson Cancer Center, Seattle
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Swedish Medical Center, Seattle
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
កំពុងជ្រើសរើសដំណាក់កាល 3
- Clinical Trial Site, Seattle
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
កំពុងជ្រើសរើស
- Fred Hutch Cancer Center, Seattle
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
កំពុងជ្រើសរើសដំណាក់កាល 3
- Swedish Medical Center, Seattle
ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions
កំពុងជ្រើសរើស
- University of Washington, Seattle
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
កំពុងជ្រើសរើសដំណាក់កាល 3
- Swedish Medical Center, Seattle
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
កំពុងជ្រើសរើសដំណាក់កាល 3
- Virginia Mason Medical Center, Seattle
- Swedish Cancer Institute, Seattle
- Fred Hutchinson Cancer Center, Seattle
- និង 1 ទៀត
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1
- Fred Hutchinson Cancer Research Center, Seattle
A Phase 1/1b Study of IAM1363 in HER2 Cancers
កំពុងជ្រើសរើសដំណាក់កាល 1
- Fred Hutchinson Cancer Center, Seattle
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
កំពុងជ្រើសរើសដំណាក់កាល 3
- Swedish Cancer Institute - Issaquah, Seattle
- Swedish Cancer Institute, Seattle
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
កំពុងជ្រើសរើសដំណាក់កាល 3
- Virginia Mason Medical Center, Seattle
- Swedish Medical Center-Ballard Campus, Seattle
- Fred Hutchinson Cancer Center, Seattle
- និង 5 ទៀត
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Fred Hutch Cancer Research, Seattle
Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery
កំពុងជ្រើសរើស
- Swedish Cancer Institute, Seattle
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Swedish Cancer Institute, Seattle
E-Mindfulness Approaches for Living After Breast Cancer
កំពុងជ្រើសរើសដំណាក់កាល 3
- Saint Joseph Medical Center Hematology and Oncology - Silverdale, Silverdale · ឆ្ងាយ 17 ម៉ាយ
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
កំពុងជ្រើសរើសដំណាក់កាល 1
- University Of Washington, Seattle
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
កំពុងជ្រើសរើសដំណាក់កាល 2
- University of Washington School of Medicine, Seattle
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Fred Hutchinson Cancer Center, Seattle
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Fred Hutchinson Cancer Center, Seattle
[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
កំពុងជ្រើសរើសដំណាក់កាល 3
- Fred Hutchinson Cancer Center, Seattle
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
កំពុងជ្រើសរើសដំណាក់កាល 3
- Fred Hutchinson Cancer Center, Seattle
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
កំពុងជ្រើសរើសដំណាក់កាល 3
- Swedish Medical Center-Ballard Campus, Seattle
- Swedish Medical Center-First Hill, Seattle
- Saint Michael Cancer Center, Silverdale · ឆ្ងាយ 17 ម៉ាយ
Quantitative MRI Assessment of Breast Cancer Therapy Response
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- University of Washington, Seattle
Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer
កំពុងជ្រើសរើសដំណាក់កាល 2
- University of Washington, Seattle
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Fred Hutchinson Cancer Center, Seattle
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Kaiser Permanente Washington, Seattle
- Swedish Medical Center-First Hill, Seattle
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
កំពុងជ្រើសរើសដំណាក់កាល 1
- Fred Hutchinson Cancer Center, Seattle
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Massive Bio SYNERGY-AI site, Seattle
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
កំពុងជ្រើសរើសដំណាក់កាល 3
- FHCC South Lake Union, Seattle
- Swedish Medical Center-First Hill, Seattle
- University of Washington Medical Center - Montlake, Seattle
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Swedish Cancer Institute, Seattle
- Seattle Cancer Care Alliance, Seattle
ការសាកល្បងសម្រាប់ មហារីកទ្រូង នៅក្នុងទីក្រុងផ្សេងទៀត
- New York City, NYការសិក្សា 134
- Houston, TXការសិក្សា 126
- Boston, MAការសិក្សា 111
- Nashville, TNការសិក្សា 80
- Los Angeles, CAការសិក្សា 72
- Edison, NJការសិក្សា 68
- St. Louis, MOការសិក្សា 64
- Durham, NCការសិក្សា 63
- Queens, NYការសិក្សា 63
- Chicago, ILការសិក្សា 58
- Philadelphia, PAការសិក្សា 56
- Dallas, TXការសិក្សា 55
ការសិក្សាផ្សេងទៀតនៅក្នុង Seattle
- Non-Small Cell Lung Cancerការសិក្សា 53
- មហារីក (គ្រប់ប្រភេទ)ការសិក្សា 49
- មហារីកតូចការសិក្សា 42
- ជំងឺលីកូសេមីមីអេឡូអ៊ីដបន្ទាន់ការសិក្សា 40
- មហារីកដែលរីករាលដាលការសិក្សា 39
- មហារីកពោះវៀនធំ និងទ្វារមាសការសិក្សា 34
- មហារីកសួតការសិក្សា 33
- មហារីកស៊ុតការសិក្សា 30
- ជំងឺ Multiple Myelomaការសិក្សា 22
- ជំងឺ Myelodysplastic Syndromesការសិក្សា 21
- ជំងឺលីកូសេមីលីម្ផូប្លាស្ទិកបន្ទាន់ការសិក្សា 21
- មហារីកប្លោកទឹកនោមការសិក្សា 21
ពី ClinicalTrials.gov, ទិន្នន័យទទួលបាននៅថ្ងៃ 5 តុលា 2026។ ការសិក្នានីមួយៗកំណត់លក្ខខណ្ឌលក្ខណៈសម្បត្តិរបស់ខ្លួន; ក្រុមការងារសិក្សាកំណត់ថាតើនរណាអាចចូលរួម។